stockrowCelcuity, Inc.
CELC Healthcare Biotechnology
- EPS
- −38.5%
- Free cash flow
- −53.3%
- Total debt
- +658.7%
Quarter to June 2026, against a year earlier
Follow CELC
Alert me
Celcuity, Inc. (CELC) Return on assets
Celcuity, Inc.'s return on assets over the twelve months to 30 June 2026 was −44.8%, up 5.0 percentage points from fiscal 2025 (−49.8%). Over the past ten years it has ranged from −59.9% (fiscal 2021) to −25.8% (fiscal 2018); the current reading is higher than 45% of that period. That is in line with the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −49.8% | 1.48 |
| FY2024 | −51.2% | (16.47) |
| FY2023 | −34.8% | (3.90) |
| FY2022 | −30.9% | 29.03 |
| FY2021 | −59.9% | (2.88) |
| FY2020 | −57.0% | (25.23) |
| FY2019 | −31.8% | (5.98) |
| FY2018 | −25.8% | 7.08 |
| FY2017 | −32.9% | 25.42 |
| FY2016 | −58.3% | (18.47) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| ELVN Enliven Therapeutics, Inc. compare | −15.0% |
| DNLI Denali Therapeutics Inc. compare | −27.2% |
| IDYA IDEAYA Biosciences, Inc. compare | −35.0% |
| CELC Celcuity, Inc. | −44.8% |
| VRDN Viridian Therapeutics, Inc. compare | −56.5% |
| DYN Dyne Therapeutics, Inc. compare | −60.3% |
| VKTX Viking Therapeutics, Inc. compare | −73.1% |
| TARS Tarsus Pharmaceuticals, Inc. compare | −135.0% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)